Mark S. Sands

10.6k citations

150 papers · 7.8k indexed · h-index 55

Physiology top 0.2%
- Lysosomal Storage Disorders Research 100
- Calcium signaling and nucleotide metabolism 14
Physiology top 0.2%
- Lysosomal Storage Disorders Research 100
- Calcium signaling and nucleotide metabolism 14
Cell Biology top 0.5%
- Cellular transport and secretion 43
Genetics top 0.5%
- Virus-based gene therapy research 26
Genetics top 1%
- Virus-based gene therapy research 26
Epidemiology
- Trypanosoma species research and implications 27
Molecular Biology
- Retinal Development and Disorders 13
- RNA Interference and Gene Delivery 12
Organic Chemistry
- Carbohydrate Chemistry and Synthesis 12

Co-authors: Carole Vogler Beth Levy E H Birkenmeier William S. Sly Shannon L. Macauley Jane E. Barker Mark E. Haskins Jonathan D. Cooper
Cited by: Physiology Cell Biology
Journals: Molecular Therapy (17 papers)Proceedings of the National Academy of Sciences (8 papers)Journal of Clinical Investigation (7 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Mark S. Sands

150 papers receiving 7.6k citations

Peers

Countries citing papers authored by Mark S. Sands

Since Specialization

Citations

This map shows the geographic impact of Mark S. Sands's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Sands with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Sands more than expected).

Fields of papers citing papers by Mark S. Sands

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Sands. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Sands. The network helps show where Mark S. Sands may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark S. Sands, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark S. Sands Line = papers co-authored together Mark S. Sands links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets Nature Reviews Neurology ·恩华杜,Anna Engströ-Laurent,Patricia Dickson,Marco Sardiello,Mark S. Sands,Jonathan D. Cooper	2025	1
2	GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice JCI Insight ·Anna Engströ-Laurent,Nicholas Rensing,恵美子中橋,Tasha S. Alexander,James B. Hamaker,Hemanth R. Nelvagal,Steven Q. Le,Marie S. Roberts,Balraj Doray,Edward B. Han,Patricia Dickson,Michael Wong,Mark S. Sands,Jonathan D. Cooper	2025	1
3	circRNAs mediate the effect of chronic lysosomal dysfunction on Alzheimer’s disease pathology Alzheimer s & Dementia ·Yusuf Ali Ahmad Harahap,Abdallah M. Eteleeb,Niko-Petteri Nykänen,雄二今井,Lv Yongmei,Oscar Harari,John R. Cirrito,Mark S. Sands,Bruno A. Benítez	2023	1
4	Gene therapy ameliorates spontaneous seizures associated with cortical neuron loss in a Cln2R207X mouse model Journal of Clinical Investigation ·Anna Engströ-Laurent,恵美子中橋,James B. Hamaker,Nicholas Rensing,Hemanth R. Nelvagal,Joshua T. Dearborn,Olivier Danos,Nicholas Buss,Mark S. Sands,Michael Wong,Jonathan D. Cooper	2023	5
5	Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome Molecular Genetics and Metabolism ·Shih‐hsin Kan,Olena VASYLIEVA,Steven Q. Le,Naike Su,Ran Xintao,Jonathan D. Cooper,Roger Lawrence,Mark S. Sands,Brett E. Crawford,Patricia Dickson	2021	2
6	Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target Proceedings of the National Academy of Sciences ·Yedda Li,Yue Xu,Bruno A. Benítez,LI Deng-jiang,Joshua T. Dearborn,Xuntian Jiang,Miguel A. Guzmán,Josh C. Woloszynek,Gabriel Oscar Fernández,Bryan K. Yip,P. Hernigou,Michael Babcock,hongjuan zhu,Stephen C. Fowler,David F. Wozniak,Carole Vogler,Jeffrey A. Medin,Brett E. Crawford,Mark S. Sands	2019	75
7	A HILIC‐MS/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum Biomedical Chromatography ·Rohini Sidhu,KingsleyR. Labrosse,Hideji Fujiwara,Mark S. Sands,Jean E. Schaffer,Daniel S. Ory,Xuntian Jiang	2018	16
8	Insights into the Pathogenesis and Treatment of Krabbe Disease. PubMed ·Ernesto R. Bongarzone,Maria L. Escolar,Steven J. Gray,Tal Kafri,Charles H. Vite,Mark S. Sands	2016	20
9	Experimental Therapies in the Murine Model of Globoid Cell Leukodystrophy Pediatric Neurology ·Yedda Li,Mark S. Sands	2014	24
10	Psychosine, the cytotoxic sphingolipid that accumulates in globoid cell leukodystrophy, alters membrane architecture Journal of Lipid Research ·Yunavaka Salsabila,C. S. Duncan,Xuntian Jiang,Paul H. Schlesinger,Ernesto R. Bongarzone,Daniel S. Ory,Alexei V. Demchenko,Mark S. Sands	2013	60
11	Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice Gene Therapy ·Coy D. Heldermon,Liu De-ba,Cédric Vermeulen,Erik D. Herzog,Jeremy R. Glissen Brown,Carole Vogler,Wei Hou,John L. Orrock,Brett E. Crawford,Mark S. Sands	2013	31
12	Central amygdala glucocorticoid receptor action promotes fear-associated CRH activation and conditioning Proceedings of the National Academy of Sciences ·Benedict J. Kolber,Marie S. Roberts,K. Chaouche-Teyara,David F. Wozniak,Mark S. Sands,Louis J. Muglia	2008	117
13	Lysosomal Dysfunction Results in Altered Energy Balance Journal of Biological Chemistry ·Josh C. Woloszynek,Trey Coleman,Clay F. Semenkovich,Mark S. Sands	2007	57
14	Critical Role of β3 Integrin in Experimental Postmenopausal Osteoporosis Journal of Bone and Mineral Research ·Haibo Zhao,Hideki Kitaura,Mark S. Sands,F. Patrick Ross,Steven L. Teitelbaum,Deborah V. Novack	2005	48
15	Marrow Stromal Cells and Osteoclast Precursors Differentially Contribute to TNF-α-Induced Osteoclastogenesis In Vivo The Journal of Immunology ·Hideki Kitaura,Mark S. Sands,一匡得地,Ping Zhou,Teruhisa Hirayama,Brian A Uthgenannt,Wei Shi,Sunao Takeshita,Deborah V. Novack,Matthew J. Silva,Yousef Abu‐Amer,F. Patrick Ross,Steven L. Teitelbaum	2004	161
16	In vivo transduction of hematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in mice Molecular Therapy ·Lingfei Xu,Aiko Unno,Mark S. Sands,Bin Wang,Todd E. Meyerrose,Mark E. Haskins,Katherine P. Ponder	2004	18
17	A Novel Model of Murine Mucopolysaccharidosis Type VII due to an Intracisternal A Particle Element Transposition into the β-Glucuronidase Gene: Clinical and Pathologic Findings Pediatric Research ·Carole Vogler,Beth Levy,Nancy Galvin,Mark S. Sands,E H Birkenmeier,William S. Sly,Jane E. Barker	2001	18
18	Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. Journal of Clinical Investigation ·Lynn H. O’Connor,Lawrence C. Erway,Carole Vogler,William S. Sly,Maribel Rocio Cana Salas,Jeffrey H. Grubb,S W Holmberg,Beth Levy,Mark S. Sands	1998	101
19	Intracisternal A-Particle Element Transposition into the Murine β-Glucuronidase Gene Correlates with Loss of Enzyme Activity: a New Model for β-Glucuronidase Deficiency in the C3H Mouse Molecular and Cellular Biology ·Babette Gwynn,Kira K. Lueders,Mark S. Sands,E H Birkenmeier	1998	37
20	Binding of TFIIIA to derivatives of 5S RNA containing sequence substitutions or deletions defines a minimal TFIIIA binding site Nucleic Acids Research ·Nan Borton,Mark S. Sands	1992	9

About Mark S. Sands

Mark S. Sands is a scholar working on Physiology, Physiology and Cell Biology, having authored 150 papers that have together received 7.8k indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (100 papers), Cellular transport and secretion (43 papers), Trypanosoma species research and implications (27 papers), Virus-based gene therapy research (26 papers), Calcium signaling and nucleotide metabolism (14 papers), Retinal Development and Disorders (13 papers), RNA Interference and Gene Delivery (12 papers) and Carbohydrate Chemistry and Synthesis (12 papers). The work is most often cited by research in Physiology (4.1k citations), Physiology (618 citations) and Cell Biology (1.6k citations). Mark S. Sands has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Carole Vogler, Beth Levy, E H Birkenmeier, William S. Sly, Shannon L. Macauley, Jane E. Barker, Mark E. Haskins, Jonathan D. Cooper, Beverly L. Davidson and Nancy Galvin. Their work appears in journals such as Molecular Therapy, Proceedings of the National Academy of Sciences, Journal of Clinical Investigation, Journal of Neuroscience and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact